HCPLive Network

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.


Further Reading
Xi E. Zheng, MD, PhD, shares her views on young-onset colorectal cancer at 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The prevalence of familial pancreatic cancer (FPC) is about 9%, and patients with FPC have more precursor lesions and are less likely to smoke than patients with sporadic pancreatic cancer, according to a study published online Oct. 14 in Cancer.
Studying vascular endothelial growth factor could lead to a new type of painkiller, according to a study published in Neurobiology of Disease.
Low-dose computed tomography is a low-cost and cost-effective strategy for screening Medicare beneficiaries for lung cancer, according to a study published in the August issue of American Health & Drug Benefits.
Do longer periods of androgen-deprivation therapy significantly improve prostate cancer survival rates or needlessly impair quality of life for recovering patients?
There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors compared to sulfonylureas and thiazolidinediones for glycemic control, according to a study published online Sept. 10 in Diabetes, Obesity and Metabolism.
Watchful waiting may not be suitable for all men with early-stage prostate cancer, especially black patients, according to research published in Urologic Oncology.
More Reading